Q-omics provides the consensus-scored IGKV2OR2-2 profile across patient tissues and cancer cell-line models. IGKV2OR2-2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, IGKV2OR2-2 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, IGKV2OR2-2 RNA expression shows 5,945 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, COAD, and BRCA as cancer lineages where IGKV2OR2-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV2OR2-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV2OR2-2 survival associations across molecular data types. IGKV2OR2-2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV2OR2-2 RNA expression–survival associations across cancer types. High IGKV2OR2-2 expression shows unfavorable associations in STAD, ACC, GBM and KIRP, but favorable associations in TGCT and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for IGKV2OR2-2 RNA expression.
This table summarizes IGKV2OR2-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGKV2OR2-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV2OR2-2 shows lower tumor expression in COAD, READ, STAD, CHOL and BRCA and higher tumor expression in LUAD. The COAD box plot shows higher IGKV2OR2-2 RNA expression in normal versus tumor tissue (log2 FC = −0.544, t-test p < 0.001).
This table shows molecular features associated with IGKV2OR2-2 in patient tissues and cancer cell lines. In patient samples, IGKV2OR2-2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
